Supported by science
Omega-3 fatty acids EPA and DHA are investigated in clinical science
for wide range of health conditions. Currently major therapeutic
application of EPA and DHA is in CVD and refers to lowering plasma
triglyceride levels. Backed by extensive scientific evidence, EPA and
DHA provide vital support to heart health in pharmaceutical
applications, lowering plasma triglycerides levels, decreasing resting
heart rate, blood pressure and inflammation, and improving vascular function.
Clinical trials referring to DHA and EPA cover such conditions as
rheumatoid arthritis, osteoporosis, stroke, traumatic brain injury,
cognitive decline, Alzheimer’s disease, depression, attention
deficit/hyperactivity disorder, macular degeneration, asthma,
inflammatory bowel disease, colon/breast/prostate cancer, skin
disorders, sarcopenia, post-surgical recovery and others.
Contact us to find out more about our broad
spectrum of EPA and DHA ingredients.